Clinical Trial Update: ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD [Phase 1, Phase 2]

View source ↗

Summary

An update on the completed Phase 1/2 safety and tolerability study of ALKS 5461 (ALKS 33-BUP) in adults with major depressive disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• ALKS 5461 (ALKS-5461)

Snippet

Sponsor: Alkermes, Inc. | Conditions: Major Depressive Disorder | Phase 1, Phase 2 | Status: COMPLETED